Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. San Camillo and Forlanini Hospitals, Rome, Italy

Survival: 14.1 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Italy
City/State/Province: Rome
Hospital: San Camillo and Forlanini Hospitals
Journal: Link
Date: 10/2009

Patients: This phase 3 study involved 950 men with castrate-refractory prostate cancer. They had previously been treated with chemotherapy, but their cancer had progressed. These men ranged in age from 42 to 95 years of age.

Treatment: These men were treated with prednisone and either the chemotherapy drug Satraplatin or placebo. A placebo is a substance that looks like the drug but does not have any activity.

Toxicity: Grade 3 and 4 toxicities that were more common in the men receiving Satraplatin than placebo included neutropenia, leucopenia, thrombocytopenia, anemia, diarrhea and infections.

Results: The median overall survival was 14.1 months (61.3 weeks) for patient treated with Satraplatin and 14.1 months (61.4 weeks) for those treated with placebo.

Support: This study was supported by research funds from Celgene and GPC Biotech. GPC Biotech has a licensing agreement with Spectrum Pharmaceuticals, Inc for satraplatin.

Correspondence: Dr. Cora N. Sternberg

E-mail to a Friend Email Physician More Information